Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Transmissible cancer and the evolution of sex.

Thomas F, Madsen T, Giraudeau M, Misse D, Hamede R, Vincze O, Renaud F, Roche B, Ujvari B.

PLoS Biol. 2019 Jun 6;17(6):e3000275. doi: 10.1371/journal.pbio.3000275. eCollection 2019 Jun.

2.

Extreme Competence: Keystone Hosts of Infections.

Martin LB, Addison B, Bean AGD, Buchanan KL, Crino OL, Eastwood JR, Flies AS, Hamede R, Hill GE, Klaassen M, Koch RE, Martens JM, Napolitano C, Narayan EJ, Peacock L, Peel AJ, Peters A, Raven N, Risely A, Roast MJ, Rollins LA, Ruiz-Aravena M, Selechnik D, Stokes HS, Ujvari B, Grogan LF.

Trends Ecol Evol. 2019 Apr;34(4):303-314. doi: 10.1016/j.tree.2018.12.009. Epub 2019 Jan 29. Review.

PMID:
30704782
3.

Individual and temporal variation in pathogen load predicts long-term impacts of an emerging infectious disease.

Wells K, Hamede RK, Jones ME, Hohenlohe PA, Storfer A, McCallum HI.

Ecology. 2019 Mar;100(3):e02613. doi: 10.1002/ecy.2613. Epub 2019 Feb 15.

PMID:
30636287
4.

Tasman-PCR: a genetic diagnostic assay for Tasmanian devil facial tumour diseases.

Kwon YM, Stammnitz MR, Wang J, Swift K, Knowles GW, Pye RJ, Kreiss A, Peck S, Fox S, Pemberton D, Jones ME, Hamede R, Murchison EP.

R Soc Open Sci. 2018 Oct 3;5(10):180870. doi: 10.1098/rsos.180870. eCollection 2018 Oct.

5.

Sex bias in ability to cope with cancer: Tasmanian devils and facial tumour disease.

Ruiz-Aravena M, Jones ME, Carver S, Estay S, Espejo C, Storfer A, Hamede RK.

Proc Biol Sci. 2018 Nov 21;285(1891). pii: 20182239. doi: 10.1098/rspb.2018.2239.

PMID:
30464069
6.

The Genomic Basis of Tumor Regression in Tasmanian Devils (Sarcophilus harrisii).

Margres MJ, Ruiz-Aravena M, Hamede R, Jones ME, Lawrance MF, Hendricks SA, Patton A, Davis BW, Ostrander EA, McCallum H, Hohenlohe PA, Storfer A.

Genome Biol Evol. 2018 Nov 1;10(11):3012-3025. doi: 10.1093/gbe/evy229.

7.

Is adaptive therapy natural?

Thomas F, Donnadieu E, Charriere GM, Jacqueline C, Tasiemski A, Pujol P, Renaud F, Roche B, Hamede R, Brown J, Gatenby R, Ujvari B.

PLoS Biol. 2018 Oct 2;16(10):e2007066. doi: 10.1371/journal.pbio.2007066. eCollection 2018 Oct.

8.

Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease.

Woods GM, Fox S, Flies AS, Tovar CD, Jones M, Hamede R, Pemberton D, Lyons AB, Bettiol SS.

Integr Comp Biol. 2018 Dec 1;58(6):1043-1054. doi: 10.1093/icb/icy118.

PMID:
30252058
9.

Large-effect loci affect survival in Tasmanian devils (Sarcophilus harrisii) infected with a transmissible cancer.

Margres MJ, Jones ME, Epstein B, Kerlin DH, Comte S, Fox S, Fraik AK, Hendricks SA, Huxtable S, Lachish S, Lazenby B, O'Rourke SM, Stahlke AR, Wiench CG, Hamede R, Schönfeld B, McCallum H, Miller MR, Hohenlohe PA, Storfer A.

Mol Ecol. 2018 Nov;27(21):4189-4199. doi: 10.1111/mec.14853. Epub 2018 Oct 5.

PMID:
30171778
10.

Genetic diversity, inbreeding and cancer.

Ujvari B, Klaassen M, Raven N, Russell T, Vittecoq M, Hamede R, Thomas F, Madsen T.

Proc Biol Sci. 2018 Mar 28;285(1875). pii: 20172589. doi: 10.1098/rspb.2017.2589. Review.

11.

Cancer Is Not (Only) a Senescence Problem.

Thomas F, Vavre F, Tissot T, Vittecoq M, Giraudeau M, Bernex F, Misse D, Renaud F, Raven N, Beckmann C, Hamede R, Biro PA, Ujvari B.

Trends Cancer. 2018 Mar;4(3):169-172. doi: 10.1016/j.trecan.2018.01.002. Review.

PMID:
29506667
12.

Evolved Dependence in Response to Cancer.

Thomas F, Kareva I, Raven N, Hamede R, Pujol P, Roche B, Ujvari B.

Trends Ecol Evol. 2018 Apr;33(4):269-276. doi: 10.1016/j.tree.2018.01.012. Epub 2018 Feb 20. Review.

PMID:
29475741
13.

Oncogenesis as a Selective Force: Adaptive Evolution in the Face of a Transmissible Cancer.

Russell T, Madsen T, Thomas F, Raven N, Hamede R, Ujvari B.

Bioessays. 2018 Mar;40(3). doi: 10.1002/bies.201700146. Epub 2018 Feb 15. Review.

PMID:
29446482
14.

The importance of cancer cells for animal evolutionary ecology.

Thomas F, Jacqueline C, Tissot T, Henard M, Blanchet S, Loot G, Dawson E, Mery F, Renaud F, Montagne J, Beckmann C, Biro PA, Hamede R, Ujvari B.

Nat Ecol Evol. 2017 Nov;1(11):1592-1595. doi: 10.1038/s41559-017-0343-z. No abstract available.

PMID:
29066812
15.

Conservation implications of limited genetic diversity and population structure in Tasmanian devils (Sarcophilus harrisii).

Hendricks S, Epstein B, Schönfeld B, Wiench C, Hamede R, Jones M, Storfer A, Hohenlohe P.

Conserv Genet. 2017 Aug;18(4):977-982. doi: 10.1007/s10592-017-0939-5. Epub 2017 Feb 7.

16.

Untangling the model muddle: Empirical tumour growth in Tasmanian devil facial tumour disease.

Hamede RK, Beeton NJ, Carver S, Jones ME.

Sci Rep. 2017 Jul 24;7(1):6217. doi: 10.1038/s41598-017-06166-3.

17.

Infection of the fittest: devil facial tumour disease has greatest effect on individuals with highest reproductive output.

Wells K, Hamede RK, Kerlin DH, Storfer A, Hohenlohe PA, Jones ME, McCallum HI.

Ecol Lett. 2017 Jun;20(6):770-778. doi: 10.1111/ele.12776. Epub 2017 May 10.

PMID:
28489304
18.

Variants in the host genome may inhibit tumour growth in devil facial tumours: evidence from genome-wide association.

Wright B, Willet CE, Hamede R, Jones M, Belov K, Wade CM.

Sci Rep. 2017 Mar 24;7(1):423. doi: 10.1038/s41598-017-00439-7.

19.

Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils.

Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, Kreiss A, Jones ME, Lyons AB, Woods GM.

Biol Lett. 2016 Oct;12(10). pii: 20160553. doi: 10.1098/rsbl.2016.0553.

20.

Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by Metabolic Profiling of Serum.

Karu N, Wilson R, Hamede R, Jones M, Woods GM, Hilder EF, Shellie RA.

J Proteome Res. 2016 Oct 7;15(10):3827-3840. Epub 2016 Sep 23.

PMID:
27599268
21.

Hematologic and serum biochemical changes associated with Devil Facial Tumor Disease in Tasmanian Devils.

Peck S, Corkrey R, Hamede R, Jones M, Canfield P.

Vet Clin Pathol. 2016 Sep;45(3):417-29. doi: 10.1111/vcp.12391. Epub 2016 Sep 2.

PMID:
27589840
22.

Rapid evolutionary response to a transmissible cancer in Tasmanian devils.

Epstein B, Jones M, Hamede R, Hendricks S, McCallum H, Murchison EP, Schönfeld B, Wiench C, Hohenlohe P, Storfer A.

Nat Commun. 2016 Aug 30;7:12684. doi: 10.1038/ncomms12684.

23.

Immunoglubolin dynamics and cancer prevalence in Tasmanian devils (Sarcophilus harrisii).

Ujvari B, Hamede R, Peck S, Pemberton D, Jones M, Belov K, Madsen T.

Sci Rep. 2016 Apr 29;6:25093. doi: 10.1038/srep25093.

24.

Hematologic and serum biochemical reference intervals for wild Tasmanian devils (Sarcophilus harrisii).

Peck S, Corkrey R, Hamede R, Jones M, Canfield P.

Vet Clin Pathol. 2015 Dec;44(4):519-29. doi: 10.1111/vcp.12304. Epub 2015 Nov 27.

PMID:
26613213
25.

Development of a SNP-based assay for measuring genetic diversity in the Tasmanian devil insurance population.

Wright B, Morris K, Grueber CE, Willet CE, Gooley R, Hogg CJ, O'Meally D, Hamede R, Jones M, Wade C, Belov K.

BMC Genomics. 2015 Oct 14;16:791. doi: 10.1186/s12864-015-2020-4.

26.

Transmissible cancer in Tasmanian devils: localized lineage replacement and host population response.

Hamede RK, Pearse AM, Swift K, Barmuta LA, Murchison EP, Jones ME.

Proc Biol Sci. 2015 Sep 7;282(1814). pii: 20151468. doi: 10.1098/rspb.2015.1468.

27.

Anthropogenic selection enhances cancer evolution in Tasmanian devil tumours.

Ujvari B, Pearse AM, Swift K, Hodson P, Hua B, Pyecroft S, Taylor R, Hamede R, Jones M, Belov K, Madsen T.

Evol Appl. 2014 Feb;7(2):260-5. doi: 10.1111/eva.12117. Epub 2013 Nov 6.

28.

Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer.

Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng Y, Belov K, Swift K, Pearse AM, Hamede R, Jones ME, Skjødt K, Woods GM, Kaufman J.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5103-8. doi: 10.1073/pnas.1219920110. Epub 2013 Mar 11.

29.

Biting injuries and transmission of Tasmanian devil facial tumour disease.

Hamede RK, McCallum H, Jones M.

J Anim Ecol. 2013 Jan;82(1):182-90. doi: 10.1111/j.1365-2656.2012.02025.x. Epub 2012 Sep 3.

PMID:
22943286
30.

New insights into the role of MHC diversity in devil facial tumour disease.

Lane A, Cheng Y, Wright B, Hamede R, Levan L, Jones M, Ujvari B, Belov K.

PLoS One. 2012;7(6):e36955. doi: 10.1371/journal.pone.0036955. Epub 2012 Jun 6.

31.

Reduced effect of Tasmanian devil facial tumor disease at the disease front.

Hamede R, Lachish S, Belov K, Woods G, Kreiss A, Pearse AM, Lazenby B, Jones M, McCallum H.

Conserv Biol. 2012 Feb;26(1):124-34. doi: 10.1111/j.1523-1739.2011.01747.x. Epub 2011 Oct 6.

PMID:
21978020
32.

Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-induced extinction.

McCallum H, Jones M, Hawkins C, Hamede R, Lachish S, Sinn DL, Beeton N, Lazenby B.

Ecology. 2009 Dec;90(12):3379-92.

PMID:
20120807
33.
34.

Life-history change in disease-ravaged Tasmanian devil populations.

Jones ME, Cockburn A, Hamede R, Hawkins C, Hesterman H, Lachish S, Mann D, McCallum H, Pemberton D.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10023-7. doi: 10.1073/pnas.0711236105. Epub 2008 Jul 14.

Supplemental Content

Loading ...
Support Center